e-learning
resources
ERJ
2004
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Penetration of newer quinolones in the empyema fluid
Liapakis I.E., Kottakis I., Tzatzarakis M.N., Tsatsakis A.M., Pitiakoudis M.S., Ypsilantis P., Light R.W., Simopoulos C.E., Bouros D.E.
Source:
Eur Respir J 2004; 24: 466-470
Journal Issue:
September
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Liapakis I.E., Kottakis I., Tzatzarakis M.N., Tsatsakis A.M., Pitiakoudis M.S., Ypsilantis P., Light R.W., Simopoulos C.E., Bouros D.E.. Penetration of newer quinolones in the empyema fluid. Eur Respir J 2004; 24: 466-470
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Thoracentesis
Effect of a pleural checklist on patient safety
Community acquired MRSA pneumonia complicated with bronchopleural fistula
Related content which might interest you:
Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections
Source: Eur Respir J 2002; 20: 3S-8S
Year: 2002
Resistance of
Streptococcus pneumoniae
to penicillin, azitromycin, ciprofloxacyn and ceftriaxon
Source: Eur Respir J 2001; 18: Suppl. 33, 140s
Year: 2001
New antibiotics for VAP
Source: Eur Respir Mon 2011; 53: 48-53
Year: 2011
Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007
Comparison of immunomodulating effects among clarithromycin, dexamethasone and levofloxacin on the murine model of
mycoplasma pneumoniae
pneumonia
Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases
Year: 2008
Pharmacokinetics and pharmacoynamics of clarithromycin in the empyema pleural fluid
Source: Eur Respir J 2004; 24: Suppl. 48, 637s
Year: 2004
Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa
Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections
Year: 2017
Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa
Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections
Year: 2014
Therapeutic efficacy of macrolides, minocycline and tosufloxacin against macrolide-resistant
Mycoplasma pneumoniae
pneumonia in pediatric patients
Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections
Year: 2012
Penetration of azithromycin in experimental pleural empyema model fluid
Source: Annual Congress 2007 - Community-acquired pneumonia: from aetiology to complication
Year: 2007
Efficacy of ciprofloxacin against resistant mucoid or non-mucoid
P. aeruginosa
isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Prevention of MRSA pneumonia by oral vancomycin decontamination: a randomised trial
Source: Eur Respir J 2004; 23: 921-926
Year: 2004
Survival benefit of beta-lactam plus macrolide combined therapy versus beta-lactam plus quinolones in hospitalized community-acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Year: 2016
Aerosolised treatment for VAP
Source: Eur Respir Mon 2011; 53: 54-65
Year: 2011
Comparison of moxifloxacin and ofloxacin in treatment of multidrug resistant pulmonary tuberculosis
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Penetration of linezolide in experimental pleural empyema model fluid
Source: Annual Congress 2007 - Community-acquired pneumonia: from aetiology to complication
Year: 2007
Use of respiratory fluoroquinolones gatifloxacin for treatment of severe community-acquired pneumonia (SCAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 166s
Year: 2006
Treatment challenges in methicillin resistant
Staphylococcus aureus
infections
Source: Annual Congress 2006 - Methicillin resistant
Staphylococcus aureus
(MRSA): a real hospital-based pathogen?
Year: 2006
Tobramycin by aerosol (Toby®) eradicates
Pseudomonas aeruginosa
resistant to Tobramycin
i.v.
in patients with infected bronchiectasis
Source: Eur Respir J 2001; 18: Suppl. 33, 542s
Year: 2001
Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia
Source: Eur Respir J 2004; 24 : 644-648
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept